INTRODUCTION
Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world and the only increasing in incidence digestive tract carcinoma. Until recently, the incidence of HCC paralleled that of the various types of viral hepatitis around the world. Additionally, cirrhosis is the most important risk factor for HCC, regardless of etiology [1] . In North America, non-alcoholic fatty liver disease (NAFLD)/ non-alcoholic steatohepatitis (NASH) is the most common cause of HCC a er hepatitis C virus (HCV), hepatitis B virus (HBV) and alcohol [2] , and one Abbreviations: ANGPT: angiopoietin-2; AFP: α-fetoprotein; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CI: con dence interval; COL: collagen; DCP: des-carboxyprothrombin; γGT: gamma glutamyl transpeptidase; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; HR: hazard ratio; ITG: integrin; LAM: laminin collagen genes; MMP: matrix metalloproteinase; MS: metabolic syndrome; NAFLD: non-alcoholic fatty liver disease; NASH: non-alcoholic steatohepatitis; PDGFRA: platelet derived growth factor receptor-α of the most important factors responsible for the increasing incidence of HCC.
e incidence of HCC not related to viral hepatitis is on the rise. It is related to lifestyle factors, including obesity and diabetes. In particular, a higher body mass index (BMI), especially among females, is a risk factor for NAFLD-HCC. Furthermore, the presence of diabetes is higher in individuals with NAFLD-HCC than in patients with HCC of other etiologies, while the presence of cirrhosis was lower in NAFLD-HCC patients. A high BMI is a poor predictor of survival, while the presence of diabetes does not in uence survival in NAFLD-HCC to any considerable degree [3] . Cirrhosis, steatosis and metabolic abnormalities play a role in the pathogenesis of NAFLD-HCC. e presence of cirrhosis usually predicts a less favorable outcome in NAFLD-HCC patients, partly owing to the fact that cirrhotic individuals also tend to be older [4] . e prevalence of NAFLD-HCC was assessed in a large sample of patient records belonging to the Veteran A airs population. NAFLD was identi ed as the third most common cause of HCC in this population, with an incidence of 8. cases of NAFLD-HCC among 1,500 cases of HCC). e annual incidence rate was found to be stable. Cirrhosis was present in only 58.3% of the NAFLD-HCC sample, which was lower than the 72.4% incidence of cirrhosis in patients with alcoholic disease-HCC and 85.6% in HCV-HCC. Hepatocellular carcinoma surveillance and treatment were less common among patients with NAFLD-HCC, although the survival rate was similar regardless of etiology [5] . A steady increase in the proportion of liver transplant recipients with NASH-HCC has been observed in a large retrospective analysis. Indeed, NASH has become the second leading cause of liver transplant among HCC patients in the USA behind only HCV, and more worrisome is the fact that NASH-HCC appears to be an everincreasing indication for liver transplant [6] .
GENOMICS, TRANSCRIPTOMICS AND METABOLOMICS
Up to 25% of NASH cases can progress to HCC [7] . A recent analysis of transcriptomic and metabolomic datasets revealed di erent genes expression in HCC evolved from NASH. No signi cant di erences were observed between samples belonging to patients with NASH with fatty liver and NASH without fatty liver. Extracellular matrix/angiogenesis genes were up-regulated in NASH patients compared to healthy patients. Among these were 5 of 24 matrix metalloproteinase genes (especially MMP14), 14 of 23 integrin genes (especially ITGA3), 7 of 12 laminin genes (especially LAMA2), and 10 of 19 collagen genes (especially COL1A2), as well as angiopoietin-2 (ANGPT2) and platelet derived growth factor receptor-α (PDGFRA). ese genes are known to be up-regulated in HCC as well, and these ndings suggest that their up-regulation occurs early during NASH and they are therefore unlikely to be associated with the progression to HCC [7] .
Iron homeostasis genes were down-regulated in NASH, including hepcidin antimicrobial peptide (HAMP), the master regulator of iron homeostasis. Also down-regulated were iron transporters solute carrier family 11, member 2 (SLC11A2, commonly called DMT1) (proton-coupled divalent metal ion transporters) and solute carrier family 39, member 14 (SLC39A14, commonly called ZIP14) (zinc transporter). On the other hand, solute carrier family 40 (iron-regulated transporter) member 1 (SLC40A1) (commonly called ferroportin1) was normal in NASH. Ferroreductases [STEAP3 and cytochrome b reductase 1 (CYBRD1)] and ferroxidases [hephaestin (HEPH)] were further dysregulated in NASH. However, the in uence of perturbed iron homeostasis on development of HCC from NASH was unclear based on these ndings [7] . Genes belonging to the Wnt signaling pathway were either up-regulated or down-regulated in NASH compared to control. Speci cally, Wnt pathway genes were generally down-regulated, while Wnt pathway inhibitor genes were up-regulated in NASH compared to control [7] . In NASH, the expression of Wnt frizzled receptors (FZD3, FZD5, FZD7) and Wnt signaling inhibitors (FRZB, SFRP5, DKK3, PRIKL1, PRIKL2, DACT1) is increased while the expression of Wnt ligands (WNT3, WNT2) and Wnt activators (FRAT1, PIN1) is decreased. While downstream genes in the Wnt pathway were generally not a ected in NASH, signalling through this pathway was shown by microarray to be largely inhibited [7] .
Several di erences were also found in terms of metabolite profiles between NASH and HCC, when comparing the findings of Clarke et al [7] with those of two previously published reports [8, 9] . Based on the cumulative data of these reports, lyso-phosphatidyl-choline metabolites were decreased in both NASH and HCC. Lysine, phenylalanine, citrulline and creatinine in plasma were decreased in HCC but were increased in NASH. In contrast, plasma glycodeoxycholic acid, creatine, inosine and α-ketoglutarate were increased in HCC and were decreased in NASH [7] [8] [9] .
e status of the cell-cycle regulator p27 was recently investigated in resected liver samples of NASH-HCC patients by Western blotting and by phosphorylation at threonine 157 (T157) and serine 10 (S10) through immunohistochemical analysis [10] . Decreased p27 expression was noted in 13 (59.1%) of 22 HCC samples, and correlated with larger tumor size (p=0.01) and increased cell proliferation (p<0.01). Phospho-p27 at T157 was noted in 4 (18.2%) of 22 patients and at S10 in 7 (31.8%) of 22 patients. p27 phosphorylation was associated with decreased disease-free survival. ese ndings suggest that p27 may be a useful biomarker of HCC recurrence in NASH-HCC [10] . e c.444C >G single nucleotide polymorphism (rs738409) in patatin-like phospholipase domain-containing 3 (PNPLA3) gene, which encodes the p.I148M (isoleucine to methionine substitution at residue 148) variant is well recognized as a modi er of hepatic triacylglycerol accumulation and NAFLD progression [11] . PNPLA3 was genotyped in peripheral blood lymphocytes. e PNPLA3 rs738409 C>G polymorphism was associated with a risk of HCC development. Male gender (p<0.0001) and the presence of cirrhosis (p<0.0001) were also associated with NAFLD-HCC [11] . The presence of the G allele was associated with NAFLD-HCC at a younger age. Furthermore, the G allele was present predominantly in younger NAFLD-HCC patients. Despite a strong association between the G allele and cirrhosis, the presence of this allele was associated with HCC regardless of the degree of brosis in a subanalysis of cirrhotic NAFLD patients with and without HCC [11] . In another study, genotypes of PNPLA3 single nucleotide polymorphism (SNP) did not di er signi cantly in a small sample of NAFLD patients between those with HCC and those without HCC [12] .
Ampli cation of chr.6p21.1 was observed in metabolic syndrome (MS)-related HCC compared to HCV-HCC, with an increased expression of cullin7 (CUL7), a gene located at this locus. is ampli cation is believed to in uence cellular proliferation [13] . liver disease. ey do not predict development of HCC from NASH [14] .
SERUM BIOMARKERS α FETOPROTEIN AND DES CARBOXYPROTHROMBIN
Alpha-fetoprotein and DCP were elevated in HCC patients compared to controls with non-malignant liver diseases [34 (20.7%) of 164 patients had NASH]. Alpha-fetoprotein was generally positive in patients with HCV-HCC or in patients with advanced stages of HCC [15] . Mean serum AFP levels measured by enzyme-linked immunosorbent assay were signi cantly higher in patients with HCV-HCC than in patients with NASH-HCC, although a large degree of within-group variability was observed in each group [16] . A trend towards higher AFP levels and a higher proportion of patients with abnormal (>10 ng/mL) AFP levels was observed at HCC diagnosis compared to NASH diagnosis in a small sample of Japanese patients with histologically-proven NASH [17] . Lower AFP levels (<20 ng/mL) were more common in NAFLD-HCC compared to alcoholic disease-HCC or HCV-HCC [5] .
In contrast, DCP was generally positive in NASH-HCC (15) . Its levels were signi cantly higher at the time of HCC diagnosis compared to the time of NASH diagnosis in a small sample of Japanese patients with histologically-proven NASH (mean 34 vs. 18 mAU/mL, p=0.004). Likewise, a higher proportion of patients had abnormal (> 40 mAU/mL) DCP levels at the time of HCC diagnosis [17] . Mean serum DCP levels measured by enzyme-linked immunosorbent assay were not di erent between HCV-HCC and NASH-HCC, although a large degree of within-group variability was observed in each group [16] .
LIPIDS AND ADIPOKINES
Lipid accumulation in hepatocytes induces cancerrelated molecular signalling through nuclear factor-κB, c-Jun N-terminal kinase/activator protein-1 activity, and overexpression of tumor growth-promoting genes [18] . Additional components include phosphatase and tensin homologue (PTEN) in hepatocytes, and the nuclear factor-κB/mammalian target of rapamycin (mTOR) complex, as well as sterol regulatory element binding proteins (SREBP), which act as master regulators of hepatic lipogenesis. Mitochondrial dysfunction and increased free fatty oxidation in peroxisomes and microsomes may lead to an excess of free reactive oxygen species and lipid peroxides that lead to oxidative stress. Oxidative stress may form adducts with DNA, leading to malignancy. Hepatic iron overload may contribute to oxidative stress. Based on these ndings, fatty liver may be a risk factor for HCC independent of MS [18] . Extrahepatic tissue, especially adipose tissue, may lead to changes in the expression and secretion of adipokines such as leptin and adiponectin, which may in uence the development of MSassociated HCC [18] .
Adiponectin increases disease-free survival in HCC, whereas leptin is significantly associated with oncogenic e ects based on the immunohistochemistry of human HCC tissue microarrays [19] . In obese individuals with MS, leptin is the main adipokine produced by the adipose tissue. Leptin has brinogenic e ects on the liver, while deregulation of the expression of leptin and its receptor were associated with metabolic disorders that can result in human cancers [20] . While some studies found leptin to be elevated in NASH compared to controls or patients with viral hepatitis, other studies failed to nd this association. At most, leptin is associated with the degree of steatosis but not with necroin ammation or brosis, which casts doubt over its association with HCC in NAFLD patients [17, 20] .
Serum leptin levels were elevated in cirrhotic patients compared to control individuals, yet no differences were observed between cirrhotic patients with and without HCC [21] . Leptin promotes pro-in ammatory and pro-brogenic e ects in NAFLD. On the other hand, adiponectin inhibits hepatic carcinogenesis. Studies have shown that leptin is upregulated and adiponectin is down-regulated in MS-related NAFLD, thereby promoting HCC. e study by Tian et al further details the proposed mechanism of action of leptin and adiponectin [22] .
INCIDENCE RATES
e incidence of NAFLD-HCC was 2.0% in a nation-wide survey in Japan (292 of 14,530 cases of HCC) [23] . Among cases of NAFLD-HCC, the median age was 72±8.4 years, gender distribution showed a proportion of 38% females, obesity, diabetes, dyslipidemia, hypertension and MS were risk factors, cirrhosis was present in 68% of the sample, while glycated hemoglobin (hemoglobin A1C) and fasting blood glucose levels were high [23] . NAFLD-HCC was more common among older white individuals, and those with cardiovascular co-morbidities such as hypertension. Lower AFP levels (<20 ng/mL) were more common among NAFLD-HCC compared to alcoholic disease-HCC or HCV-HCC [5] .
Hepatocellular carcinoma was not one of the predominant malignancies in a large sample of NAFLD patients (age ≥ 60 years). It occurred in 10 individuals (6.0% of 167 individuals with malignancies and 0.6% of 1,600 NAFLD patients). Predictive factors for malignancies in NAFLD patients were older age (≥70 years), smoking, low platelet count (<150×10 3 / μL) and higher glucose levels. On the other hand, liver enzyme levels [alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyl transpeptidase (γGT)] were not risk factors [24] .
A low HCC incidence of 0.25% was observed in a retrospective cohort study in a large sample of NAFLD patients diagnosed by ultrasound (16 of 6,508 NAFLD patients) [25] (HR 8.20 , 95% CI 1.09-9.50, p=0.035) were independent risk factors for HCC. Hepatocellular carcinoma was associated with signi cant brosis assessed by the AST to platelet ratio index (APRI) (equivalent to stage 3-4 NASH, HR 25.03, 95% CI 9.02-69.52, p<0.001) but not by the BARD score [25] .
Hepatocellular carcinoma occurred in comparable numbers of males and females in a small sample of Japanese patients with histologically-proven NASH (n=19, 52.6% female) [17] . In this sample, HCC was diagnosed a er a median follow-up of 3.8 years since NASH diagnosis, during which time the degree of brosis became more advanced in all patients, with J Gastrointestin Liver Dis, December 2014 Vol. 23 No 4: 425-429 no signi cant change in the degree of steatosis. BMI, platelet count and ALT levels were signi cantly lower at the time of HCC diagnosis compared to the time of NASH diagnosis, with no di erences in AST and gGT levels.
e incidence of NAFLD-HCC was 2.0% in a national survey investigating the etiology of HCC in Japan. Older age, male gender, advanced liver brosis, lower activity of liver histology, lower ALT and higher γGT levels were detected as risk factors for HCC in NAFLD patients. However, advanced brosis remains one of the predominant risk factors for HCC development [26] . e probability of having bridging brosis or cirrhosis on liver biopsy is approximately 66% in patients with cryptogenic cirrhosis who are older, overweight/obese and diabetic. is may re ect referral bias to hepatologists in tertiary referral centers. NAFLD has a much higher prevalence in the elderly population. A prevalence rate of 46% for NAFLD detected by ultrasound was reported in a cohort of healthy octogenarians admitted to the rehabilitation wards of a geriatric hospital [27] . is rate was signi cantly higher than that found in a younger population [28] .
In addition, new prognostic biomarkers include microRNAs both in NAFLD and alcoholic liver disease during the transition from simple non-in amed steatosis to hepatocarcinoma [28, 29] . NAFLD is a common cause of cirrhosis and end-stage liver disease; it is more common in the population of elderly people than in younger groups. e challenge is to understand this paradox and the natural history of patients with NAFLD before the disease leads to HCC.
CONCLUSIONS
In people diagnosed with NAFLD/NASH, a better medical and laboratory surveillance is necessary to treat the disease in time and to avoid HCC development. ere is a need for a multidisciplinary team and a more active approach to ensure speci c and sensitive understanding of the clinical evolution of the disease and interpretation of the results. Monitoring the patients is the only solution to ensure an early detection and a better prognosis for NAFLD-HCC patients.
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